… ) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients
… myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. …

… ) inhibitors such as captopril reduce mortality and cardiovascular morbidity among patients
… myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both. …

… for HF, valsartan was as effective as captopril. There was no … the effect of captopril, valsartan,
or captopril plus valsartan on … -cause mortality, cardiovascular mortality, HF hospitalizations…

… heart failure, or both were enrolled in the VALIANT Echo study. Patients were randomized to
… valsartan 160 mg PO BID, captopril 50 mg PO TID, or valsartan 80 mg PO BID plus captopril …

… non-inferiority of the ARB valsartan 160 mg bid compared with captopril 50 mg tds, when …
with left ventricular dysfunction or heart failure in the immediate post myocardial infarction …

… With the demonstrated effectiveness of ACE inhibitors in reducing the risk of death, heart
failure, and recurrent infarction in patients with acute MI, the reference treatment in VALIANT …

… valsartan was as effective as captopril at reducing mortality in patients with acute MI complicated
by heart failure, LVSD, or both… % CI for valsartan compared with captopril was within the …

… The VALsartan In Acute myocardial infarction (VALIANT) trial enrolled 14,703 patients
with myocardial infarction complicated by heart failure or documented left ventricular systolic …

… and safety of long-term treatment with valsartan, captopril, or both in high-risk patients after
MI. … 10 days of acute MI complicated by clinical HF, LV systolic dysfunction, or both. Details of …

… in myocardial infarction was complementary to the other proven … the development of heart
failure after myocardial infarction. … of valsartan and captopril is superior to captopril alone in the …